Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 13,100 shares, an increase of 67.9% from the January 15th total of 7,800 shares. Based on an average daily trading volume, of 66,100 shares, the short-interest ratio is presently 0.2 days. Currently, 0.3% of the shares of the stock are short sold.

Evogene Trading Up 4.5 %

NASDAQ EVGN traded up $0.07 on Friday, hitting $1.55. 10,024 shares of the company’s stock were exchanged, compared to its average volume of 27,162. The stock has a 50-day moving average of $1.57 and a 200-day moving average of $2.37. Evogene has a 52 week low of $1.20 and a 52 week high of $10.40. The stock has a market cap of $8.31 million, a price-to-earnings ratio of -0.35 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last released its earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Evogene in a research note on Friday. They issued a “sell” rating for the company.

Institutional Investors Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene at the end of the most recent reporting period. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.